<DOC>
	<DOCNO>NCT01423435</DOCNO>
	<brief_summary>A study evaluate pharmacokinetics safety TRK-100STP Japanese , Chinese , South Korean non-elderly healthy adult male .</brief_summary>
	<brief_title>Study Compare Pharmacokinetic Profiles TRK-100STP Japanese , Chinese , South Korean Non-elderly Healthy Adult Males</brief_title>
	<detailed_description />
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>Body weight : = &lt; 50.0 80.0 &gt; kg BMI : = &lt; 17.6 26.4 &gt; Subjects whose condition investigator/subinvestigator confirm healthy date drug administration , base screen test result Subjects received investigational drug within 120 day prior screen test clinical trial postmarketing study Subjects 400 mL whole blood draw within 90 day prior screen test , 200 mL whole blood draw within 30 day prior screen test , component blood draw within 14 day prior screen test Subjects receive receive drug treatment include counter ( OTC ) drug within 7 day prior day confinement Subjects whose vital sign standard level one follow parameter time screen test day confinement : blood pressure , pulse rate , body temperature , 12lead ECG Subjects upper GastroIntestinal ( GI ) symptom within 7 day prior day confinement ( 1 day prior drug administration ) : nausea , vomit , stomachache Subjects complication history liver disease : viral hepatitis chronic bronchitis Subjects complication history Cardio Vascular ( CV ) diseases : chronic heart failure , angina , arrythmia need treatment Subjects complication history respiratory disease : severe bronchial asthma chronic bronchitis . History pediatric asthma include Subjects complication history respiratory disease : severe peptic ulceration gastroesophageal reflux disease . History appendicitis include Subjects complication history renal disease : acute renal failure , glomerulonephritis , interstitial nephritis . History calculus include Subjects complication history cerebrovascular disease include cerebral infarction Subjects complication history malignant tumor Subjects daily amount alcohol smoke excessive Subjects receive beraprost</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>TRK-100STP</keyword>
	<keyword>PK</keyword>
	<keyword>beraprost sodium</keyword>
</DOC>